NCT02303405

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Comparing the Effects of Hydroxychloroquine (HCQ) to Pioglitazone in Type 2 Diabetic Patients Failing Maximal Doses of Metformin Plus a Sulfonylurea

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Charles Drew University of Medicine and Science · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.

Detailed description

A 4-month, randomized, prospective, open-label comparison trial of 4 months of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.

Conditions

• Diabetes Mellitus Type 2 With Hyperglycemia

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Anti-inflammatory and anti-malarial agent
DRUG	Pioglitazone	Anti-hyperglycemic agent

Timeline

• Start date: 2014-11-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2014-11-27
• Last updated: 2022-10-20
• Results posted: 2022-10-20

Locations

1 site across 1 country: United States